Praxis Precision Medicines annual ebitda
2019
2020
2021
2022
2023
2024
2025
Praxis Precision Medicines EBITDA Growth & History (PRAX)
Praxis Precision Medicines's calculated EBITDA was −$326.1M for fiscal 2025.
View full Praxis Precision Medicines company overviewPraxis Precision Medicines annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$326.1M | −$126.3M | — |
| 2024 | 2024-12-31 | −$199.8M | −$73.9M | — |
| 2023 | 2023-12-31 | −$125.9M | $88.6M | — |
| 2022 | 2022-12-31 | −$214.6M | −$47.4M | — |
| 2021 | 2021-12-31 | −$167.2M | −$105.2M | — |
| 2020 | 2020-12-31 | −$61.9M | −$26.2M | — |
| 2019 | 2019-12-31 | −$35.8M | — | — |
Praxis Precision Medicines quarterly ebitda
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$96.9M | −$20.9M | — |
| Q1 2026 | 2026-03-31 | −$105.8M | −$31.1M | — |
| Q4 2025 | 2025-12-31 | −$97.0M | −$33.1M | — |
| Q3 2025 | 2025-09-30 | −$78.3M | −$21.6M | — |
| Q2 2025 | 2025-06-30 | −$76.0M | −$38.6M | — |
| Q1 2025 | 2025-03-31 | −$74.7M | −$32.9M | — |
| Q4 2024 | 2024-12-31 | −$63.9M | −$36.2M | — |
| Q3 2024 | 2024-09-30 | −$56.7M | −$31.3M | — |
| Q2 2024 | 2024-06-30 | −$37.4M | −$2.5M | — |
| Q1 2024 | 2024-03-31 | −$41.8M | −$3.8M | — |
| Q4 2023 | 2023-12-31 | −$27.7M | $13.7M | — |
| Q3 2023 | 2023-09-30 | −$25.4M | $18.8M | — |
| Q2 2023 | 2023-06-30 | −$34.9M | $25.4M | — |
| Q1 2023 | 2023-03-31 | −$38.0M | $30.8M | — |
| Q4 2022 | 2022-12-31 | −$41.3M | $17.2M | — |
| Q3 2022 | 2022-09-30 | −$44.2M | $546,000 | — |
| Q2 2022 | 2022-06-30 | −$60.3M | −$23.8M | — |
| Q1 2022 | 2022-03-31 | −$68.8M | −$41.4M | — |
| Q4 2021 | 2021-12-31 | −$58.6M | −$32.9M | — |
| Q3 2021 | 2021-09-30 | −$44.7M | −$28.5M | — |
| Q2 2021 | 2021-06-30 | −$36.5M | −$24.9M | — |
| Q1 2021 | 2021-03-31 | −$27.4M | −$18.9M | — |
| Q4 2020 | 2020-12-31 | −$25.7M | — | — |
| Q3 2020 | 2020-09-30 | −$16.2M | — | — |
| Q2 2020 | 2020-06-30 | −$11.6M | — | — |
| Q1 2020 | 2020-03-31 | −$8.5M | — | — |
Praxis Precision Medicines ebitda trends
Over the last five reported fiscal years, Praxis Precision Medicines's ebitda decreased from −$61.9M to −$326.1M, a change of −$264.1M. The latest reported quarter, Q2 2026, shows −$96.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Praxis Precision Medicines filings at SEC.gov ↗